關(guān)鍵信息

    治療上皮性卵巢癌（EOC）的歷史標(biāo)準(zhǔn)是卡鉑+紫杉醇。依據(jù)非隨機(jī)研究，劑量密集化療可能提高晚期疾病的應(yīng)答率，而耐受性可以保持。

    該綜述的作者評(píng)估了使用紫杉醇強(qiáng)化治療晚期EOC的基本原理和III期試驗(yàn)結(jié)果。

    TAKE-HOME MESSAGE

    The historical standard of care for advanced epithelial ovarian cancers （EOC） is carboplatin and paclitaxel. Based on nonrandomized studies, dose-dense chemotherapy may improve response rates in advanced disease, and tolerability may be maintained.

    The authors of this review evaluate the rationale and phase III trial results associated with dose-dense delivery of paclitaxel in advanced EOC.